Pfizer to buy Biohaven for $11.8 billion, reveals the Financial Times
The venerable Financial Times this morning revealed that US pharma giant Pfizer is in the advanced stages of buying Biohaven, a US-listed firm that has been working on treatments for migraines.
Date:Tuesday, 10 May 2022 2:22 pm
